Journal of Biological Chemistry
Volume 271, Issue 37, 13 September 1996, Pages 22782-22790
Journal home page for Journal of Biological Chemistry

Cell Biology and Metabolism
Differential Intrinsic Enzymatic Activity of Syk and Zap-70 Protein-tyrosine Kinases*

https://doi.org/10.1074/jbc.271.37.22782Get rights and content
Under a Creative Commons license
open access

Syk and Zap-70 are related protein-tyrosine kinases implicated in antigen and Fc receptor signaling. While Zap-70 is restricted to T-cells and natural killer cells, Syk accumulates in B-cells, mast cells, platelets, and immature T-cells. In addition, we found that an isoform of Syk (SykB), which carries a 23-amino acid deletion in the “linker” region, is prominently expressed in bone marrow. To better understand the relative impact of Syk, SykB, and Zap-70 on signal transduction, we compared their intrinsic enzymatic properties in transiently transfected COS-1 cells and in hemopoietic cells. Using modified versions of these enzymes bearing a common Myc epitope at the amino terminus, we determined that the ability of Syk and SykB to undergo autophosphorylation and to phosphorylate erythrocyte band 3 in immune complex kinase reactions was at least 100-fold greater than that of Zap-70. Similarly, Syk and SykB, but not Zap-70, caused prominent tyrosine phosphorylation of p120c-cbl in COS-1 cells. A similar pattern of activity was also noted for endogenous Syk and Zap-70 from hemopoietic cells. To understand the structural basis for these characteristics, we also created and analyzed a series of chimeras between Syk and Zap-70. These studies indicated that the catalytic domain of Syk and Zap-70, but not their SH2 domains, linker region or carboxyl-terminal tail, was responsible for their respective activity. Taken together, these data demonstrated that the intrinsic enzymatic activity of Syk and SykB is superior to that of Zap-70 and that such a distinction relates to structural variations in the catalytic domain.

Cited by (0)

*

This work was supported by grants from the Cancer Research Society Inc., the Medical Research Council of Canada, the National Cancer Institute of Canada, and the Leukemia Research Fund of Canada. The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§

Supported by a Fellowship from the Leukemia Research Fund of Canada.

∥∥

Supported by a Steve Fonyo Studentship from the National Cancer Institute of Canada.